Folate depletion increases sensitivity of solid tumor cell lines to 5-fluorouracil and antifolates

International Journal of Cancer

Volumn 87, Issue 6, 2000, Pages 771-778

  Backus, H H J ^a   Pinedo, H M ^a   Wouters, D ^a   Padron J M ^a,b   Molders, N ^a   Van Der Wilt, C L ^a   Van Groeningen, C J ^a   Jansen, G ^a   Peters, G J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b DSM RESEARCH   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DIHYDROFOLATE REDUCTASE; FLUOROURACIL; FOLIC ACID; FOLINIC ACID; FOLYLPOLYGLUTAMATE SYNTHASE; NALPHA (4 AMINO 4 DEOXYPTEROYL) NDELTA HEMIPHTHALOYLORNITHINE; NOLATREXED; PEMETREXED; PLEVITREXED; RALTITREXED; REDUCED FOLATE CARRIER; THYMIDYLATE SYNTHASE;

ARTICLE; BINDING SITE; CANCER CELL CULTURE; CATALYSIS; COLON CARCINOMA; DRUG SENSITIVITY; DRUG TRANSPORT; FOLIC ACID DEFICIENCY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CARRIER PROTEINS; COLONIC NEOPLASMS; FLUOROURACIL; FOLIC ACID; FOLIC ACID ANTAGONISTS; HEAD AND NECK NEOPLASMS; HUMANS; LEUCOVORIN; LUNG NEOPLASMS; MEMBRANE PROTEINS; MEMBRANE TRANSPORT PROTEINS; MICE; MULTIENZYME COMPLEXES; NEOPLASMS; PEPTIDE SYNTHASES; TETRAHYDROFOLATE DEHYDROGENASE; THYMIDYLATE SYNTHASE; TUMOR CELLS, CULTURED;

EID: 0033845077     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0215(20000915)87:6<771::AID-IJC2>3.0.CO;2-V     Document Type: Article

References (63)

1. Augmentation of the therapeutic activity of lometrexol: (6-R)-5,10-dideazatetrahydrofolate by oral folic acid
2. Structural features of 5,10-dideaza-5,6,7,8-tetrahydrofolate that determine inhibition of mammalian glycinamide ribonucleotide formyltransferase
3. Relationship of dUMP an FdUMP pools to inhibition of thymidylate synthase by 5-fluorouracil
4. Ode to methotrexate
5. A rapid and sensitive method for the quantitaion of micogram quantities of protein utilizing the principle of protein-dye binding
6. Clinical studies with MTA
7. An overview of folate metabolism: Features relevant to the action and toxicities of antifolate anticancer agents
8. Establishment of epidermoid carcinoma cell lines
9. Open, randomised, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer
10. Evaluation of single agents and combinations of chemotherapeutic agents in mouse colon carcinomas
11. Increase in thymidylate synthase protein levels measured using newly developed antibodies
12. Intrinsic and acquired resistance to methotrexate in acute leukemia
13. In vitro uptake, anabolism, and cellular retention of 1843U89 and other benzoquinazoline inhibitors of thymidylate synthase
14. Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2
15. ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and IN VIVO: A new agent for clinical study
16. Folate-based thymidylate synthase inhibitors as anticancer drugs
17. Cellular pharmacology and in vivo activity of a new anticancer agent, ZD9331: A water-soluble, nonpolyglutamatable, quinazoline-based inhibitor of thymidylate synthase
18. Expression of a folate binding protein in L1210 cells grown in low folate medium
19. Measurement of folylpolyglutamate synthetase activity in head and neck squamous carcinoma cell lines and clinical samples using a new rapid separation procedure
20. Regulation of carrier-mediated transport of folates and antifolates in methotrexate-sensitive and-resistant leukemia cells
21. A structurally altered human reduced folate carrier with increased folic acid transport mediates a novel mechanism of antifolate resistance
22. Comparison of the sulforhodamine B protein and tetrazolium (MTT) assays for in vitro chemosensitivity testing
23. Possible link between intrinsic drug resistance of colon tumors and a detoxification mechanism of intestinal cells
24. MRP3, an organic anion transporter able to transport anti-cancer drugs
25. Increased growth inhibition and DNA lesions in human colon aenocarcinoma cells treated with methotrexate and 5-fluorodeoxy-uridine followed by calmodulin inhibitors
26. Thymidylate synthase as a target for growth inhibition in methotrexate-sensitive and -resistant human head and neck cancer and leukemia cell lines
27. Enhancement of the anti-tumor effects of 5-fluorouracil by folinic acid
28. Chemotherapy of gastrointestinal cancer
29. Chemotherapy of gastrointestinal cancer
30. Overview of phase II trials of MTA in solid tumors
31. Diurnal variation in the therapeutic efficacy of 5-fluorouracil against murine colon cancer
32. Transformation of mouse fibroblasts with the oncogenes H-ras or trk is associated with pronounced changes in drug sensitivity and metabolism
33. Thymidylate synthase inhibition after administration of 5-fluorouracil with or without leucovorin: Implications for treatment with 5-fluorouracil
34. New antimetabolites in preclinical and clinical development
35. Principles of antineoplastic drug development and pharmacology
36. Fluoropyrimidines as antifolate drugs. Anticancer drug development guide: Antifolate drugs in cancer therapy
37. Determinants of activity of the antifolate thymidylate synthase inhibitors tomudex (ZD1694) an GW1843U89 against mono- and multilayered colon cancer cell lines under folate-restricted conditions
38. Molecular downstream events and induction of thymidylate synthase in mutant and wild-type p53 colon cancer cell lines after treatment with 5-fluorouracil and the thymidylate synthase inhibitors Raltitrexed
39. Pharmacokinetics of leucovorin metabolites in human plasma as a function of dose administered orally and intravenously
40. Modulation of thymidylate synthase expression by dietary folic acid-induced DNA hypomethylationin a mouse model tumour
41. Preclinical and phase I clinical studies with the nonclassical antifolate thymidylate synthase inhibitor Nolatrexed dihydrochloride given by prolonged administration in patients with solid tumors
42. Impact of schedule on leucovorin potentiation of fluorouracil antitumor activity in dietary folic acid deplete mice
43. Overview of phase I trials of multitargetted antifolate (MTA, LY231514)
44. Biochemical studies on PT523, a potent nonpolyglutamatable antifolate, in cultured cells
45. PT523 an other aminopterin analogs with a hemiphthaloyl-L-ornithine side chain: Exceptionally tight-binding inhibitors of dihydrofolate reductase which are transported by the reduced folate carrier but cannot form polyglutamates
46. Induction of in vivo resistance against gemcitabine (dFdC, 2',2'-difluoro-deoxycytidine)
47. Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: A phase II study
48. Thymidylate synthase inhibitors in cancer therapy: Direct and indirect inhibitors
49. New colometric assay for anticancer drug screening
50. LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes
51. Impact of dietary folic acid on reduced folates in mouse plasma and tissues: Relationship to dideazatetrahydrofolate sensitivity
52. Mechanisms of innate resistance to thymidylate synthase inhibition after 5-fluorouracil
53. Folate-based thymidylate synthase inhibitors in cancer chemotherapy
54. A dideazatetrahydrofolate analogue lacking a chiral center at C-6; N-[4-[2-2-amino-1,7-dihydro-4-oxopyrrolo[2,3-d]pyrimidin-6-yl)-et hyl]-benzoyl]-glutamic acid, a new and potent inhibitor of thymidylate synthase
55. Mutations in the reduced folate carrier gene which confer dominant resistance to 5,10-dideazatetrahydrofolate
56. Cellular folates prevent polyglutamation of 5,10-dideazatetrahydrofolate
57. In vitro activity of novel antifolates against human squamous carcinoma cell lines of the head and neck with inherent resistance to methotrexate
58. Screening of colon tumor cells and tissues for folylpolyglutamate synthetase activity
59. The role of folates in the chemosensitivity to Tomudex, LY231514 and 5-fluorouracil/leucovorin of murine tumour models
60. Thymidylate synthase levels as the main predictive parameter for sensitivity to 5-fluorouracil, but not for folate-based thymidylate synthase inhibitors, in 13 non-selected colon cancer cell lines
61. AG337, a novel lipophilic thymidylate synthase inhibitor: In vitro and in vivo pre-clinical studies
62. Further studies on a novel class of genetic variants of the L1210 cell with increased folate analogue transport inward
63. Functional folate status as a prognostic indicator of toxicity in clinical trials of the multi-targeted antifolate LY231514